Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: A new era of hormonal therapies is born

Keyphrases

• Prostate Cancer 100%
• Androgens 100%
• Abiraterone 100%
• Hormonal Therapy 100%
• Clinical Trials 50%
• Placebo 50%
• Rational Design 50%
• Abiraterone Acetate 50%
• Castration-resistant Prostate Cancer 50%
• Taxanes 50%
• Androgen Signaling 50%
• Sipuleucel-T 50%
• Therapeutic Strategies 50%
• MDV3100 50%
• Enzalutamide 50%
• TAK-700 50%
• U.S. Food 50%
• Advanced Prostate Cancer 50%
• Design Basis 50%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 50%
• Cabazitaxel 50%
• Oncogenic Pathways 50%
• Overall Survival 50%
• Survival Benefit 50%
• Luteinizing Hormone 50%
• Specific Inhibitor 50%
• Co-agonist 50%
• Androgen Synthesis 50%
• Cytochrome P450 17 50%
• Pregnenolone 50%
• Prolonged Life 50%
• TOK-001 50%
• Orteronel 50%
• ARN-509 50%
• Galeterone 50%
• Androgen-independent 50%
• Cancer Growth 50%
• Autologous Immunotherapy 50%
• Targetable 50%
• Parent Structure 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Hormone Cancer Therapy 100%
• Prostate Cancer 100%
• Abiraterone 100%
• Androgen 100%
• Enzalutamide 40%
• Clinical Trial 20%
• Placebo 20%
• Abiraterone Acetate 20%
• Sipuleucel T 20%
• Cancer Growth 20%
• Cabazitaxel 20%
• Overall Survival 20%
• Gonadorelin Agonist 20%
• Agonist-Antagonist 20%
• Cytochrome P450 Family 17 20%
• Pregnenolone 20%
• Orteronel 20%
• Galeterone 20%
• Carcinogenesis 20%
• Immunotherapy 20%
• Nitrofen 20%
• Taxane 20%